Birt--Hogg--Dubé syndrome, also called Hornstein--Knickenberg syndrome, is an inherited disorder characterized by skin fibrofolliculomas, pulmonary cysts, pneumothorax, and renal tumors.[@b1],[@b2] Renal cell carcinoma is the most serious and life-threatening manifestation. Since the discovery of the responsible gene, named *FLCN*,[@b3] increasing numbers of BHD patients have been diagnosed by genetic testing.[@b4]--[@b6] Bilateral and metachronous RCCs are often observed.[@b5],[@b6] Patients are at risk for developing independent tumors in the remaining renal tissues after surgical intervention. However, many physicians are still not aware of BHD-related symptoms, and undiagnosed patients are treated as sporadic RCC. Characterization of RCC associated with BHD is important to identify previously undiagnosed patients.

With regard to histological features, only a few studies have been published.[@b5]--[@b7] Birt--Hogg--Dubé syndrome is morphologically characterized as a HOCT and composites of more than one histological type.[@b5] Hybrid oncocytic/chromophobe tumor is an oncocytic neoplasm that has areas suggestive of chromophobe RCC and oncocytoma. Many large eosinophilic cells possess intracytoplasmic vacuoles.[@b5],[@b8] However, for a patient with an unknown genetic background, these renal tumors are virtually indistinguishable from sporadic ones solely by microscopic findings. Hybrid oncocytic/chromophobe tumor might also be found in individuals without an *FLCN* germline mutation.[@b9]--[@b11] Detailed information about diagnostic markers for *FLCN*-related RCC is unavailable.

In the current study, we investigated the pathological features and expression of FLCN and another key molecule, GPNMB, in RCCs of BHD patients. Recently, GPNMB was identified as a downstream targeting molecule induced by FLCN inactivation.[@b12] Here we show that RCCs with *FLCN* germline mutations overexpressed GPNMB and that they tended to lose the intact form of FLCN. Sporadic renal tumors showed inverted expression patterns of GPNMB and FLCN.

Materials and Methods
=====================

Samples
-------

Eighteen patients (17 families) were enrolled in this study, providing 27 renal tumors (Tables[2](#tbl2){ref-type="table"}). Written informed consent was obtained from each patient. The study was approved by the Institutional Review Board of Yokohama City University (Yokohama, Japan). Resected tissues were fixed with 10% buffered formalin and embedded in paraffin. Hematoxylin and eosin staining was carried out for histological diagnosis. In seven tumors, RCCs and normal parts of the kidneys were snap-frozen and stored in liquid nitrogen until use. Sporadic renal tumors (*n* = 62) were used for comparison. The possibilities of von Hippel-Lindau disease, tuberous sclerosis complex, hereditary papillary RCC, and hereditary leiomyomatosis RCC were carefully examined and excluded in all patients by thorough medical examination and family history. The following points were checked in the studied cases in accordance with the diagnostic criteria proposed by the European BHD Consortium[@b1]: (i) pulmonary cysts; (ii) fibrofolliculomas; (iii) pneumothorax; (iv) familial history of pneumothorax, fibrofolliculoma, and renal tumor; and (v) multiple RCC or hybrid features in histology. All patients who were diagnosed with BHD by genetic testing had at least two manifestations. In the sporadic tumor groups, one patient with unilateral chromophobe RCC had pulmonary cysts and genetic testing was carried out. Other patients diagnosed with sporadic renal tumors did not have any of the manifestations listed above. Histological types were determined by two pathologists with expertise in renal tumors (N. Kuroda and Y. Nagashima).

###### 

Summary of clinical information of patients with Birt--Hogg--Dubé syndrome (BHD)

  Family no.        Gender   Age, years   No. of RCC   Treatments               Other findings                     Prognosis (follow-up period, months)
  ----------------- -------- ------------ ------------ ------------------------ ---------------------------------- --------------------------------------
  BHD1              Female   46           1            Nx                       PTX, PC                            NED (30)
  BHD2 (proband)    Female   69           2            Rt. Nx                   Skin tumors, PC                    NED (54)
  BHD2 (daughter)   Female   46           1            Lt. NSS                  PC                                 NED (42)
  BHD3              Male     61           1            Nx, VATS                 PTX, PC                            Lung metastasis NED (42)
  BHD4              Male     67           3            Lt. Nx                   Skin tumors, PC, Adrenal adenoma   NED (30)
  BHD5              Male     54           \>5          Lt. Nx, Rt. NSS          PC                                 NED (27)
  BHD6              Male     65           \>5          Bilateral Nx             PTX, PC                            Dyalisis NED (25)
  BHD7              Male     56           1            Lt. Nx                   PTX, PC                            Lung metastasis DOD (78)
  BHD8              Male     79           3            Unoperated               PTX, PC, Prostatic Ca.             DEAD (23)
  BHD9              Female   68           3            Lt. NSS                  PTX, PC Skin tumors                NED (18)
  BHD10             Female   45           5            Lt. Nx, Rt. Unoperated   PTX, PC Thyroid Ca.                AWD (390)
  BHD11             Male     48           2            Lt. Nx, Rt. NSS          PTX, PC                            NED (174)
  BHD12             Female   29           1            Lt. NSS                  PTX, PC                            NED (19)
  BHD13             Male     63           2            Rt. Nx                   PTX, PC Skin tumors                NED (18)
  BHD14             Female   46           1            Rt. NSS                  PC                                 NED (9)
  BHD15             Female   65           1            Lt. NSS                  PTX, PC                            NED (9)
  BHD16             Male     45           3            Lt. Nx                   PTX, PC                            NED (9)
  BHD17             Female   49           2            Lt. and Rt. NSS          PC                                 NED (9)

AWD, alive with disease; Ca, carcinoma; DEAD, died of prostatic cancer; DOD, died of disease; Lt., left; NED, no evidence of disease; NSS, nephron-sparing surgery; Nx, nephrectomy; PC, pulmonary cysts; PTX, pneumothorax; RCC, renal cell carcinoma; Rt., right; VATS, video-associated thoracic surgery.

###### 

Summary of genetic and histopathological information in patients with Birt--Hogg--Dubé syndrome (BHD)

  Sample no.                                    Histology                                          Germline mutation of *FLCN*     Somatic mutation of *FLCN*                                  IHC    
  --------------------------------------------- -------------------------------------------------- ------------------------------- ----------------------------------------------------------- ------ -------------
  BHD1                                          Chromophobe                                        Exon 11c.1285dupC               ND                                                          ND     ND
  BHD2-T1 (proband)                             Unclassified                                       Exon 5c.332_349del              Exon 13 c.1528_1530delGAG[†](#tf2-1){ref-type="table-fn"}   (++)   Cytoplasmic
  BHD2-T2 (proband)                             Unclassified                                       Exon 5c.332_349del              NA[†](#tf2-1){ref-type="table-fn"}                          (++)   Cytoplasmic
  BHD2-T3 (daughter)                            HOCT                                               Exon 5c.332_349del              Exon 6 c.453delGT                                           (++)   Cytoplasmic
  BHD3                                          Papillary                                          Exon 13 c.1533_1536delGATG      ND                                                          ND     ND
  BHD4-T1                                       Chromophobe                                        Exon 11c.1285dupC               NA[†](#tf2-1){ref-type="table-fn"}                          ND     ND
  BHD4-T2                                       Chromophobe                                        Exon 11c.1285dupC               Undetectable[†](#tf2-1){ref-type="table-fn"}                ND     ND
  BHD4-T3-Chr[‡](#tf2-2){ref-type="table-fn"}   Chromophobe                                        Exon 11c.1285dupC               ND                                                          (++)   Cytoplasmic
  BHD4-T3-P[§](#tf2-3){ref-type="table-fn"}     Papillary                                          Exon 11c.1285dupC               ND                                                          (−)    (−)
  BHD4-T3-Cle[¶](#tf2-1){ref-type="table-fn"}   Clear cell                                         Exon 11c.1285dupC               ND                                                          (−)    (−)
  BHD5                                          HOCT                                               Exon 13 c.1533_1536delGATG      Exon 5c.327_328delCC[†](#tf2-1){ref-type="table-fn"}        (++)   (−)
  BHD6                                          Unknown                                            Exon 11c.1285dupC               ND                                                          ND     Not done
  BHD7                                          Papillary                                          Exon 11c.1285dupC               Exon 11 LOH                                                 (++)   Cytoplasmic
  BHD8                                          Oncocytic tumor[††](#tf2-4){ref-type="table-fn"}   Exon 13 c.1533_1536delGATG      NA[†](#tf2-1){ref-type="table-fn"}                          ND     ND
  BHD9-T1                                       Chromophobe                                        Exon 11c.1285dupC               Undetectable                                                (++)   Nuclear
  BHD9-T2                                       HOCT                                               Exon 11c.1285dupC               Exon 10 c.1174delC                                          (++)   Cytoplasmic
  BHD10                                         HOCT                                               Exon 11c.1285dupC               Exon 10 c.1174delC[†](#tf2-1){ref-type="table-fn"}          (++)   Cytoplasmic
  BHD11-T1                                      Chromophobe                                        Exon 9c.906dupT                 ND                                                          (++)   Cytoplasmic
  BHD11-T2                                      Chromophobe                                        Exon 9c.906dupT                 ND                                                          (+)    Cytoplasmic
  BHD12                                         HOCT                                               Exon 11c.1285dupC               ND                                                          (+)    Cytoplasmic
  BHD13-T1                                      Chromophobe                                        Exon 12c.1347_1353 dupCCACCCT   NA[†](#tf2-1){ref-type="table-fn"}                          (++)   Cytoplasmic
  BHD13-T2                                      Clear cell                                         Exon 12c.1347_1353 dupCCACCCT   NA[†](#tf2-1){ref-type="table-fn"}                          (−)    (−)
  BHD14                                         Chromophobe                                        Exon12c.1429 C\>T               Exon 11c.1234 delGinsAGA                                    (+)    Cytoplasmic
  BHD15                                         Chromophobe                                        Exon 11c.1285dupC               Undetectable                                                (++)   Cytoplasmic
  BHD16-T1                                      HOCT                                               Exon 13 c.1533_1536delGATG      ND                                                          (++)   Cytoplasmic
  BHD16-T2                                      Calcified nodule                                   Exon 13 c.1533_1536delGATG      ND                                                          ND     ND
  BHD16-T3                                      Calcified nodule                                   Exon 13 c.1533_1536delGATG      ND                                                          ND     ND
  BHD17-T1                                      Chromophobe                                        Exon 11c.1285dupC               Exon 11 LOH                                                 (++)   Cytoplasmic
  BHD17-T2                                      Chromophobe                                        Exon 11c.1285dupC               Undetectable                                                (++)   Nuclear

DNA was extracted from paraffin-embedded tumors.

Chromophobe lesion of BHD4-T3.

Papillary lesion of BHD4-T3. ¶Clear cell lesion of BHD4-T3.

Detailed histological analysis was not available due to postmortal autolysis. GPNMB immunostaining patterns were scored as: (−), no staining or \<5% positive tumor cells; (+), occasional weak staining in ≥5% tumor cells; (++), moderate or intense staining in ≥5% tumor cells. FLCN, folliculin; GPNMB, glycoprotein non-metastic B; HOCT, hybrid oncocytic chromophobe tumor; IHC, immunohistochemistry; LOH, loss of heterozygosity; NA, not available; ND, not done; T, tumor.

Antibodies
----------

For Western blotting of FLCN, rabbit mAb D14G9 (Cell Signaling Technology, Danvers, MA, USA) was used. For FLCN immunostaining, we used rabbit polyclonal antibody ab93196 (Abcam, Cambridge, UK) was used. For GPNMB immunostaining and Western blotting, we obtained goat polyclonal antibody AF-2550 (R&D Systems, Minneapolis, MN) was used. Mouse mAb against β-actin was purchased from Sigma (St. Louis, MO, USA).

Immunostaining
--------------

Four micrometer-thick paraffin sections were subjected to immunohistochemistry. For GPNMB immunostaining, sections were treated with proteinase K for 10 min at room temperature. For other antibodies, sections were autoclaved at 121°C for 15 min. The sections were treated with the diluted antibodies at 4°C overnight. Working dilutions were 1:200 for GPNMB and 1:50 for anti-FLCN antibody (ab93196). The FLCN immunostaining patterns were scored as follows. Tissues lacking staining or with \<5% positive tumor cells regardless of cytoplasmic or nuclear pattern were termed "negative" (−). Weak to strong cytoplasmic staining without nuclear staining in ≥5% tumor cells was defined as "cytoplasmic". Weak to strong nuclear staining regardless of cytoplasmic staining in ≥5% tumor cells was termed "nuclear". The GPNMB immunostaining patterns were scored as follows: no staining or \<5% positive tumor cells was categorized as "negative" (−); occasional weak staining in ≥5% tumor cells was categorized as (+); and moderate or intense staining in ≥5% tumor cells was categorized as (++).

DNA isolation
-------------

DNA from peripheral blood leukocytes was obtained using the LabPass Blood Mini kit (Cosmo Genetech, Seoul, Korea), and DNA from renal tissue was obtained using QIAamp DNA Mini kit (Qiagen, Hidden, Germany) according to the manufacturers' instructions.

Direct sequencing
-----------------

Exons 4--14 of the *FLCN* gene were amplified by PCR using the primers described previously.[@b3] The PCR conditions were described in our previous study.[@b13] After purification, DNA was labeled with the Big Dye Terminator version 1.1 Cycle Sequencing Kit (Applied Biosystems, Cleveland, OH, USA) and DNA sequencing was done using an ABI Prism 3100 Genetic Analyzer (Applied Biosystems).

Western blot analysis
---------------------

Lysates (12.5 μg protein) were electrophoresed on SDS-PAGE and transferred to a PVDF membrane (Millipore, Billerica, MA, USA). Horseradish peroxidase-conjugated donkey anti-goat IgG and goat anti-rabbit IgG and anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as the secondary antibodies. Bands were detected using an enhanced chemiluminescence system, according to the Hybond ECL protocol (GE Healthcare, Chalfont St. Giles, UK).

RNA isolation
-------------

Total RNAs from renal frozen tissues were obtained using RNeasy Mini kit (Qiagen) according to the manufacturer\'s instructions.

Quantitative RT-PCR
-------------------

The QuantiTect SYBR Green PCR kit (Qiagen) was used for quantitative RT-PCR. Conditions for PCR were as follows: 50°C for 2 min, 95°C for 15 min, 40 cycles at 95°C for 30 s, and 60°C for 30 s. *GAPDH* was used as an internal control gene. The primers used for real-time PCR were: *GPNMB*, (F) 5′-TGCGAGATCACCCAGAACACA-3′ and (R) 5′-CGTCCCAGA- CCCATTGAAGGT-3′;[@b12] *GAPDH*, (F) 5′-CCACCCATG GCAAATTCC-3′ and (R) 5′-TGATGGGATTTCCATTGATGAC-3′. The mRNA levels were expressed as the absolute number of copies normalized against *GAPDH* mRNA. Differences in amplification were determined using the standard curve method.

Somatic mutation analysis of *FLCN* in renal tumors
---------------------------------------------------

DNA was extracted from renal tumor tissues. If only the germline mutational signal was amplified and the wild-type sequence was unreadable, it was determined that LOH occurred as the second hit. Exons other than genetically mutated sites were also amplified, and if somatic intragenic mutation was suggested, the PCR product was subcloned and sequenced to clarify the second hit.

Results
=======

Clinical histories and *FLCN* mutation patterns
-----------------------------------------------

Patient characteristics are summarized in Table[1](#tbl1){ref-type="table"}. All the patients in this study were Japanese, and the patient group included nine women and nine men. Two patients had lung metastases. One of them (BHD7) had a 10-cm-sized solitary RCC and multiple lung metastases at the time of diagnosis. The patient died 78 months after nephrectomy and successive chemotherapy and targeting therapies. All of the patients had pulmonary cysts and four patients had skin tumors.

The C8 tract in exon 11 (c.1285dupC) was the most frequent germline mutation pattern. It was detected in 9 of 18 patients. Deletion of GATG in exon 13 (c.1533_1536delGATG) was detected in four patients. Other affected families showed different mutation patterns (Table[2](#tbl2){ref-type="table"}).

In the sporadic RCC group, one patient with unilateral chromophobe RCC had a few small air cystic spaces in the lung. Although the patient and family members had neither fibrofolliculoma nor pneumothorax, genetic testing was carried out. No mutation was detected, and the possibility of BHD was excluded. Other patients diagnosed with sporadic tumors did not have any manifestation related to BHD, thus genetic testing was not carried out.

Histology of *FLCN*-related renal tumors
----------------------------------------

Two patients were excluded from histological study. Patient BHD8 died of a prostatic tumor and had not undergone surgery; at autopsy, renal tumors showed autolysis. Patient BHD6 experienced chronic renal failure. Twelve tumor lesions were pathologically diagnosed as chromophobe RCCs (44.4%), six tumors were HOCTs (22.2%), three tumor lesions were papillary RCCs (11.1%), and two tumor lesions were clear cell RCCs (7.4%). In BHD4, one of three tumors (BHD4-T3) was composed of more than one histological type. In BHD16, two tumors were mostly replaced by calcified material. In BHD2-proband, two independent tumors were diagnosed as unclassified.[@b14]

Chromophobe RCCs and HOCTs grew in an expansive manner. A few cystic tubules were composed of low columnar benign-looking cells that were intermingled in the peripheries or the centers of the tumors. That is, intratumoral peripheral small papillary tufts[@b15] were associated with fibrotic stroma or thick-walled blood vessels (Fig.[1a](#fig01){ref-type="fig"},b, arrows). In some areas, tumor cells looked clear due to intracytoplasmic vacuoles (Fig.[1c](#fig01){ref-type="fig"},d).

![Histological and gross features of *FLCN*-related renal tumors. (a, b) H&E staining of chromophobe renal cell carcinoma (RCC) in Birt--Hogg--Dubé (BHD) syndrome patient BHD13 (a) and hybrid oncocytic/chromophobe tumor (HOCT) in BHD5 (b). A few benign-looking cystic tubules migrated in tumor nodules (arrows). (c, d) High magnification of chromophobe RCC in BHD17 (c) and HOCT in BHD10 (d). HOCT is composed of oncocytoma-like granular cells with round nuclei and chromophobe RCC-like cell borders and perinuclear halo. (e) Sectioned surface of BHD7 shows a brownish solid tumor. (f, g) H&E staining of papillary RCC in BHD7 at low magnification (f) and high magnification (g). (h) Tumor cells were diffusely immunostained for α-methylacyl-CoA racemase, supporting the histology of papillary RCC.](cas0106-0315-f1){#fig01}

Somatic mutations of *FLCN*
---------------------------

Possible somatic mutations of *FLCN* were investigated in 16 tumors (7 freshly frozen tumors and 9 paraffin-embedded tumors). Second hit intragenic mutations were detected in 6 tumors. In these tumors, the second hits occurred in a different exon from the genetically affected exon (Table[2](#tbl2){ref-type="table"}). Among them, in BHD9-T2, monoallelic mutations between exon 10 and exon 11 were identified by the cloning (Figs[2a](#fig02){ref-type="fig"},S1). It was unknown in the other five tumors which allele was affected due to large-sized intervening introns or the quality of DNA from paraffin-embedded tumors. Apart from six tumors with second hits, two tumors showed LOH (Fig.[2b](#fig02){ref-type="fig"}) in which the heterozygous mutation pattern was completely replaced by a hemizygous mutation pattern. The germline mutation was retained and the wild-type allele was lost, thus both copies were affected.

![Germline and somatic mutation patterns of *FLCN*. (a) Birt--Hogg--Dubé (BHD) syndrome patient BHD9 carried *FLCN* germline mutation in exon 11 (upper left). The exon 10 sequence was confirmed to be wild-type (lower left). The patient\'s tumor BHD9-T2 showed somatic mutation in exon 10 (lower right) in addition to germline mutation (upper right). (b) BHD17 carried *FLCN* germline mutation in exon 11 (left). The mutation pattern was c.1285dupC. In the tumor lesion, heterozygous mutation in the C8 tract was completely replaced by a C9 tract, indicating loss of heterozygosity (right). No additional mutation was found in the other exons. Arrows indicate starting point of mutation.](cas0106-0315-f2){#fig02}

Expression of FLCN protein in BHD and sporadic renal tumors
-----------------------------------------------------------

Next, we investigated FLCN protein expression. Using the antibody D14G9 for Western blotting, the FLCN bands (70 kDa) stained strongly in non-tumor regions of BHD kidneys, whereas FLCN bands were either undetectable or much weaker in RCCs of BHD patients, compared with the corresponding non-tumor parts (Fig.[3a](#fig03){ref-type="fig"}). In sporadic tumors, the FLCN bands were clearly detected (Fig.[3b](#fig03){ref-type="fig"}). We also obtained similar results using antibodies sc-25168 and ab93196 (data not shown).

![Folliculin (FLCN) expression in Birt--Hogg--Dubé (BHD) and sporadic tumors. (a) Representative results of Western blot analysis of BHD kidneys. Patients BHD9 and BHD17 had two independent tumors (T1, T2). The FLCN bands (70 kDa) were clearly detected in non-tumor lanes but barely seen in tumor lanes. N, normal-looking region; T, tumor region. (b) Representative results of Western blotting analysis of sporadic renal tumors and normal kidneys without the background of BHD. Sporadic renal tumors include clear cell renal cell carcinomas (RCCs) (*n* = 3), oncocytoma (*n* = 1), papillary RCC (*n* = 1), and chromophobe RCCs (*n* = 3).](cas0106-0315-f3){#fig03}

We carried out FLCN immunostaining using the antibody ab93196 (Fig.[4](#fig04){ref-type="fig"}). The staining sensitivity and intensity of this product were the best among the three examined antibodies. In normal renal cortices, FLCN was strongly stained in the nuclei and cytoplasms of distal tubules and collecting ducts (Fig.[4a](#fig04){ref-type="fig"},b). The majority of *FLCN*-related tumors showed weak cytoplasmic staining (Table[2](#tbl2){ref-type="table"}, Fig.[4c](#fig04){ref-type="fig"},e,g). Nuclear staining was observed in only two *FLCN*-related tumors. In normal areas of BHD kidneys, strong nuclear staining was detected (Fig.[4c](#fig04){ref-type="fig"},e,g, insets). In sporadic cases, most tumors (except chromophobe RCCs) showed nuclear staining. In chromophobe RCCs, 11 of 18 cases showed nuclear staining (61.1%) (Table[3](#tbl3){ref-type="table"}, Fig.[4d](#fig04){ref-type="fig"},f,h).

###### 

Summary of folliculin (FLCN) and glycoprotein non-metastic B (GPNMB) immunostaining in Birt--Hogg--Dubé (BHD) and sporadic renal tumors

  Immunostaining   HOCT/oncocytoma   Chromophobe   Papillary   Clear cell                                
  ---------------- ----------------- ------------- ----------- ------------ -------- --------- --------- ----------
  FLCN                                                                                                   
   Nuclear         0 (0)             6 (75)        2 (22)      11 (61)      0 (0)    9 (82)    0 (0)     16 (80)
   Cytoplasmic     5 (83)            2 (25)        7 (78)      6 (33)       1 (50)   0 (0)     0 (0)     1 (5)
   Negative        1 (17)            0 (0)         0 (0)       1 (6)        1 (50)   2 (18)    2 (100)   3 (15)
  GPNMB                                                                                                  
   (−)             0 (0)             8 (100)       0 (0)       9 (50)       1 (50)   10 (91)   2 (100)   20 (100)
    (+)            1 (17)            0 (0)         2 (22)      8 (44)       0 (0)    1 (9)     0 (0)     0 (0)
    (++)           5 (83)            0 (0)         7 (78)      1 (6)        1 (50)   0 (0)     0 (0)     0 (0)

(−), No staining or \<5% of the tumor cells positive; (+), occasional weak staining; (++), moderate or intense staining. HOCT, hybrid oncocytic chromophobe tumor.

![Folliculin (FLCN) immunostaining in normal kidney, and Birt--Hogg--Dubé (BHD) and sporadic tumors. (a) H&E staining of a normal kidney. (b) Serial section of sample A immunostained for FLCN. Nuclei of distal tubules were strongly positive for FLCN. (c--h) Immunostaining for FLCN in BHD and sporadic tumors. Weak cytoplasmic staining was evident in tumors of BHD patients (c, e, h). Insets highlight distal tubules of non-tumor areas, showing immunoreactivity to FLCN. Sporadic renal tumors (d, f, h) showed strong nuclear staining.](cas0106-0315-f4){#fig04}

Overexpression of GPNMB protein in FLCN-related tumors
------------------------------------------------------

Western blotting clearly indicated the loss of FLCN, but immunostaining for FLCN was not sufficiently specific to predict RCC associated with BHD. Some auxiliary markers were desirable to give an indication for genetic analysis. In the current study, we compared GPNMB expression between BHD and sporadic tumors. In quantitative RT-PCR, RCCs from BHD patients expressed *GPNMB* mRNA at levels that averaged 23-fold higher compared to sporadic RCCs (*P *\< 0.01, Student\'s *t*-test) (Fig.[5a](#fig05){ref-type="fig"}). *GPNMB* mRNA levels of non-neoplastic renal tissues of BHD patients were as low as those of sporadic RCCs (data not shown).

![Glycoprotein non-metastatic B (GPNMB) expression in Birt--Hogg--Dubé (BHD) and sporadic tumors. (a) Expression levels of *GPNMB* mRNA were analyzed by quantitative RT-PCR as shown. Sporadic renal tumors include clear cell renal cell carcinomas (RCCs) (*n* = 9), oncocytoma (*n* = 1), papillary RCC (*n* = 1), and chromophobe RCCs (*n* = 6). (b) Representative results of Western blot analysis of BHD kidneys. Patients BHD9 and BHD17 had two independent tumors (T1, T2), respectively. Two isoforms (115 kDa and 80 kDa) of GPNMB bands were seen in tumor lanes, but not in normal-looking lanes. N, normal-looking region; T, tumor region. (c) Representative results of Western blot analysis of sporadic renal tumors and normal kidneys without the background of BHD. GPNMB bands were barely seen in sporadic tumor and normal kidney lanes. Sporadic renal tumors included clear cell RCCs (*n* = 3), oncocytoma (*n* = 1), papillary RCC (*n* = 1), and chromophobe RCCs (*n* = 4). PC, positive control using BHD9-T2.](cas0106-0315-f5){#fig05}

In Western blot analysis, strong expression of GPNMB protein was detected only in *FLCN*-related tumors, and the bands were undetectable in non-tumor renal tissues of BHD patients. The GPNMB bands were barely detectable in sporadic RCCs and normal kidneys (Fig.[5b](#fig05){ref-type="fig"},c).

Immunostaining revealed that GPNMB was undetectable in normal control kidneys (Fig.[6](#fig06){ref-type="fig"}). All *FLCN*-related RCCs (except for three non-chromophobe RCCs) were positively stained for GPNMB (Table[2](#tbl2){ref-type="table"}, Fig.[6b](#fig06){ref-type="fig"},d). Immunostaining intensities of GPNMB were correlated with the relative expression of *GPNMB* mRNA, such that BHD15 with intense staining showed the highest expression whereas BHD2 with moderate staining showed lower expression compared with BHD15. Small nodules of renal oncocytosis in non-tumor regions, which is one of the diagnostic characteristics of BHD kidneys,[@b5] also showed moderate immunostaining (Fig.[6f](#fig06){ref-type="fig"}). In sporadic cases, half of the chromophobe RCCs and most other types were negatively stained for GPNMB (Table[3](#tbl3){ref-type="table"}). Importantly, all sporadic oncocytomas were negative for GPNMB, whereas all HOCTs in BHD were positively stained. With regard to GPNMB-positive RCCs, all but one showed nuclear staining for FLCN. Only one GPNMB-positive RCC showed cytoplasmic staining for FLCN. The patient with this tumor also had a few pulmonary cysts. Genetic testing was carried out and the possibility of BHD was eliminated.

![Glycoprotein non-metastatic B (GPNMB) immunostaining of Birt--Hogg--Dubé (BHD) and sporadic tumors. (a, c, e) H&E staining of BHD tumors (T) of patients BHD2-T1 (a), BHD13-T1 (c), and a nodule of oncocytosis in the normal-looking region (N) of BHD13 (e, dotted circle). (b, d, f) Serial sections of (a, c, e) immunostained for GPNMB. Tumor cells (b, d) were intensely stained for GPNMB. Tubules of normal-looking regions were negative for GPNMB. GPNMB was immunostained in the region of focal oncocytosis (f, dotted circle). (g--i) Immunostaining for GPNMB in sporadic renal tumors: papillary renal cell carcinoma (g), oncocytoma (h), and chromophobe renal cell carcinoma (i). Insets are H&E stains of the serial sections.](cas0106-0315-f6){#fig06}

Discussion
==========

Several important signaling pathways are affected by FLCN deficiency, including mTOR and the MiTF family.[@b12],[@b16]--[@b18] We confirmed overexpression of phospho-S6, a downstream molecule of mTOR complex 1, in *FLCN*-related RCCs (data not shown). However, mTOR pathway molecules are also overexpressed in sporadic RCCs.[@b19],[@b20] These ubiquitously upregulated molecules cannot be used for differential diagnosis.

A previous analysis of *FLCN*-related RCCs revealed frequent somatic frameshift mutations or LOH.[@b21] *In situ* hybridization analysis indicated that *FLCN* mRNA was undetectable in the RCCs of BHD patients.[@b22] The results of the current study supported the notion that the intact form of FLCN protein is lost in RCCs of BHD patients. However, immunohistochemical studies of a substantial number of *FLCN*-related RCCs have not been carried out due to the specificity and sensitivity of antibodies.[@b23] Investigators using a non-commercial polyclonal antibody reported strong immunostaining for FLCN in a BHD renal tumor with a second hit in the *FLCN* gene.[@b24] We recognize that the antibody ab93196 showed strong nuclear staining in normal renal tubules. HeLa cells transiently transfected with *FLCN* showed nuclear staining *in vitro*.[@b16] Nuclear accumulation of FLCN in normal cells has also been described in published reports.[@b23] Therefore, a weak cytoplasmic staining *in vivo* might alert us to the possibility of BHD. The pathophysiological significance of nuclear localization of FLCN is poorly understood, and further study is needed.

In the present study, the expression of *GPNMB* mRNA was significantly higher in *FLCN*-related RCCs than in sporadic tumors, data that were supported by Western blotting. However, half of the sporadic chromophobe RCCs showed weak immunostaining for GPNMB. It should be noted that all of these RCCs showed a nuclear staining for FLCN. Although immunoreactivity for GPNMB alone cannot be sufficiently specific to predict RCC associated with BHD, a combined immunohistochemical panel for FLCN and GPNMB might predict appropriate cases for genetic testing. One sporadic RCC case with pulmonary cysts showed the immunostaining patterns suggestive of *FLCN*-related tumors. Although genetic testing excluded the possibility of BHD, careful follow-up is needed to better understand the unusual clinicopathological features of this case. Sporadic chromophobe RCCs rarely have somatic *FLCN* mutations but potentially have promoter methylation and LOH.[@b25],[@b26] Therefore, further studies are needed to understand the role of FLCN in sporadic RCCs.

Little is known about the roles of GPNMB in the human kidney. Glycoprotein non-metastatic B is upregulated in monocytes and macrophages in dialysis patients, suggesting that it has a role as an inflammatory mediator in a uremic milieu.[@b27] Glycoprotein non-metastatic B plays an essential role in osteoblast maturation and osteoclast differentiation[@b28] and is also involved in melanosome formation.[@b29] In previous work on GPNMB in FLCN signaling, FLCN inactivation induced nuclear accumulation of TFE3, allowing the production of GPNMB.[@b12] We also examined immunostaining of TFE3 in the current cases, but TFE3-positive cells were sparse (data not shown), suggesting that the overexpression of GPNMB might not be an event explained solely by the FLCN--TFE3 axis. Not only MiTF family members[@b30] but also growth factors[@b31] were reported to be involved in the cascade. For example, β-fibroblast growth factor and platelet-derived growth factor were shown to induce GPNMB overexpression in skeletal muscle cells.[@b31] Although the detailed role of GPNMB in RCC needs to be analyzed in greater detail, the present study suggests that GPNMB is expressed more abundantly in *FLCN*-related RCC than sporadic RCC.

We suggest that urologists and pathologists should carefully analyze the background of unusual renal tumors with multifocal growth. It is hoped that our study of FLCN and GPNMB expression might help distinguish *FLCN*-related RCCs from sporadic tumors. It is important to understand the detailed role of GPNMB in renal carcinogenesis in BHD patients. Further studies will also be needed to find additional useful markers in the diagnosis of *FLCN*-related RCCs.
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BHD

:   Birt--Hogg--Dubé syndrome

FLCN

:   folliculin

GPNMB

:   glycoprotein non-metastatic B

HOCT

:   hybrid oncocytic/chromophobe tumor

LOH

:   loss of heterozygosity

MiTF

:   microphthalmia-associated transcription factor

mTOR

:   mammalian target of rapamycin

RCC

:   renal cell carcinoma

TFE3

:   transcription factor E3
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**Fig. S1.** Cloning from exon 10 to exon 11 of folliculin (FLCN) in Birt--Hogg--Dubé (BHD) syndrome patient BHD9-T2. Exon 10 (114 bp) and exon 11 (124 bp) are intervened by intron 10 (565 bp). The sequence results of four clones (Nos. 1C--4C) are shown. Ex10 and Ex11 indicate wild-type sequences. Clone-2 (No. 2C) simultaneously shows somatic mutation in exon 10 (second line from the top) and germline mutation in exon 11 (bottom line).
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